Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 47pembrolizumab 37Magnetic Resonance Spectroscopy 33Specimen Handling 27Radiotherapy, Intensity-Modulated 21Cetuximab 19Nivolumab 18Carboplatin 16Platinum 151,2-diaminocyclohexaneplatinum II citrate 15Radiotherapy 14Biopsy 12Paclitaxel 11Gemcitabine 10Docetaxel 10Surveys and Questionnaires 9Radiation 9Immunoglobulin G 7Disulfides 7toripalimab 6cemiplimab 6Ipilimumab 6Fluorouracil 6Bevacizumab 6dostarlimab 5atezolizumab 5Watchful Waiting 5Taxes 5Immune Checkpoint Inhibitors 5Drug Therapy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tiragolumab × Head & Neck × 30 days × Clear all
NCT05681039 2026-06-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
29 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡